The latter half of that paragraph is articulating what I think Theranos is currently doing, not what I think they should have done.
What I said they should have done is described to their investors the business model that would act as a stop gap measure (gain market share and revenues by using existing technology) while allowing them to develop their proprietary technology to a point where it can get regulatory approval and can replace the already existing tech they're currently using.
> Leading investors to believe that you have technology that will be ready in 2011 when in reality you expect it to be ready in 2016 is not flipping a start up business model... It's just lying to get investor money
I've not seen any indication that rounds were predicated on certain delivery dates of the tech (what tech? what is the "success" percent? can the tech be augmented with more traditional tools?). If terms did get that specific, then there would be grounds for potential fraud.
What I said they should have done is described to their investors the business model that would act as a stop gap measure (gain market share and revenues by using existing technology) while allowing them to develop their proprietary technology to a point where it can get regulatory approval and can replace the already existing tech they're currently using.
> Leading investors to believe that you have technology that will be ready in 2011 when in reality you expect it to be ready in 2016 is not flipping a start up business model... It's just lying to get investor money
I've not seen any indication that rounds were predicated on certain delivery dates of the tech (what tech? what is the "success" percent? can the tech be augmented with more traditional tools?). If terms did get that specific, then there would be grounds for potential fraud.